Teva launches authorized generic of Minastrin 24 Fe as oral contraceptive

Teva Pharmaceuticals Industries Ltd. has launched its authorized generic of Minastrin 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) 1 mg/20 mcg in the U.S.
The Authorized Generic of Minastrin 24 Fe, an estrogen/progestin combined oral contraceptive, is designed to prevent pregnancy in females of reproductive age, though Teva notes that efficacy has not been evaluated in women with a body mass index of more than 35 kg/m2. By adding this generic drug to its portfolio, Teva now has more than 50 oral contraceptives. One of every two oral contraceptive prescriptions in the U.S. involves a Teva-marketed product.
Additionally, Teva is the largest supplier of FDA-approved generic medications in the U.S.
The company noted that Minastrin 24 Fe had annual sales of roughly $361 billion in the U.S. as of December 2016, according to data from IMS.